Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3480

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3480
---
 Any of these factors may prevent us from completing our preclinical studies and clinical trials that we
may initiate or commercializing any product candidates we may develop on a timely or profitable basis, if at all.

Due
to our business model, we must make decisions on the allocation of resources to certain programs and product candidates; these decisions
may prove to be wrong and may adversely affect our business.

We
may forego or delay pursuit of opportunities with respect to additional research programs or product candidates or for indications other
than those we are currently targeting. To the extent we allocate resources to any particular product candidate, our ability to pursue
development of another product candidate may be hindered. Some of these opportunities may later prove to have greater commercial potential
or a greater likelihood of success. Therefore, our resource allocation decisions may cause us to fail to capitalize on viable commercial
products or profitable market opportunities, or expend resources on product candidates that are not viable.

There
can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop
suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and
prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to
be unsuccessful.

We
may not be successful in our efforts to identify or discover additional product candidates in the future.

Although
our business model relies in part on a plan to harness breakthrough inventions at research universities and medical centers and develop
them into therapeutics that can address unmet medical needs, there can be no assurance that we will ever be able to identify additional
candidate opportunities at these institutions or others. Even if we were able to identify such opportunities, there can be no assurance
that we will be able to in-license them or otherwise acquire rights to them on terms that are beneficial to us. Furthermore, we could
face competition for such opportunities from other companies and from venture capital firms.

Our
research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical
development for a number of reasons, such as:

    ●
    our
    inability to design such product candidates with the pharmacological properties that we desire or attractive pharmacokinetics; or

    ●
    potential
    product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they
    are unlikely to be medicines that will receive marketing approval and achieve market acceptance.

Research
programs to